Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type A (Stydy NB02T)
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Botulinum toxin B (Primary)
- Indications Dystonia
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 10 Jul 2018 Status changed from recruiting to completed.
- 23 Dec 2016 Planned End Date changed to 1 Dec 2018.
- 23 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2017.